As of Jan 13
| +0.10 / +0.85%|
The 7 analysts offering 12-month price forecasts for Cytokinetics Inc have a median target of 17.00, with a high estimate of 24.00 and a low estimate of 15.00. The median estimate represents a +43.46% increase from the last price of 11.85.
The current consensus among 6 polled investment analysts is to Buy stock in Cytokinetics Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.